Table IV.
PKPD parameter estimates and 95% credible intervals obtained for moxifloxacin and NCE05
| Moxifloxacin | NCE05 | ||||
|---|---|---|---|---|---|
| Dogs (n = 8) | Monkeys (n = 8) | Healthy subjects (n = 24) | Monkeys (n = 6) | Healthy subjects (n = 24) | |
| QTc0 [ms] | 240 (238–242) | 341 (337–347) | 399 (394–403) | 367 (349–390) | 378 (373–383) |
| Sex effect [ms] | N/A | N/A | 8 (5–12) | N/A | N/A |
| α | 0.28 (0.22–0.35) | 0.48 (0.36–0.64) | 0.40 (0.38–0.42) | 0.55 (0.50–0.60) | 0.26 (0.23–0.31) |
| A [ms] | 4.6 (3.1–7.0) | 14.9 (10.1–22.3) | 2.4 (1.7–2.9) | 7.6 (2.6–21) | 4.2 (2.6–5.8) |
| φ [h] | 23.1 (15.1–34.6) | 24.9 (20.6–30.2) | 10.0 (7.3–12.9) | 24 (20–29) | 8.1 (5.2–11) |
| Slope [ms/nM] | 0.00056 (0.00002–0.0014) | 0.0016 (0.0008–0.0026) | 0.0039 (0.0033–0.0044) | 0.022 (0.0097–0.041) | 0.0052 (−0.0048–0.016) |
| BSV (QT0) % | 6.46 (6.43–6.48) | 5.41 (5.37–5.45) | 5.01 (4.98–5.04) | 5.2 (5.1–5.2) | 5.2 (5.1–5.2) |
| BSV (α) % | 86 (48–177) | 51 (27–110) | 41 (33–52) | 1.9 (1.0–4.4) | 19 (13–29) |
| BSV (A) % | 9.8 (7.4–14.8) | 10.4 (8.1–15.2) | 5.3 (3.6–8.0) | 2.6 (1.6–5.2) | 8.2 (5.0–14) |
| BSV (φ) % | 13 (8–23) | 6.2 (4.1–10.3) | 18 (10–31) | 3.2 (1.6–7.9) | 16 (8.1–34) |
| BSV (Slope) % | 25 (17–39) | 36 (25–58) | 41 (29–53) | 42 (23–99) | 37 (21–87) |
| Residual Error [ms] | 9.4 (9.3–9.5) | 10.0 (9.8–10.3) | 5.3 (5.2–5.4) | 7.4 (6.8–8.1) | 16 (13–19) |
| Prob ≥10 ms at Cmax | 1.0 | 1.0 | 1.0 | 1.0 | 0 |
| Cmax [nM] | 112,930 | 31,400 | 10,300 | 8660 | 101 |